Table 1.
Baseline characteristics of allogeneic HCT recipients.
| Characteristic | AlloHCT with IFD (n = 52) | AlloHCT Recipients without IFD (n = 421) | p-Value |
|---|---|---|---|
| Hematological disease, n | 0.324 | ||
| AML | 26 | 216 | |
| ALL | 18 | 87 | |
| MDS | 4 | 32 | |
| CML | 2 | 25 | |
| NHL | 1 | 32 | |
| PMF | 1 | 19 | |
| Other | 10 | ||
| Type of donor, n | 0.012 | ||
| Graft from a matched sibling donor | 10 | 232 | |
| Graft from a matched unrelated donor | 31 | 164 | |
| Graft from an alternative donor | 11 | 25 | |
| HCT, n | 0.127 | ||
| HCT in complete remission in CR | 41 | 369 | |
| HCT in active disease | 11 | 52 |
HCT, Hematopoietic cell transplantation; IFD, Invasive fungal disease; AML, Acute myeloid leukemia; ALL, Acute lymphoblastic leukemia; MDS, Myelodysplastic syndrome; CML, Chronic myeloid leukemia; NHL, Non-Hodgkin lymphoma, PMF; Primary myelofibrosis; CR, Complete remission.